% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kessler:277801,
      author       = {T. Kessler$^*$ and D. Schrimpf$^*$ and L. Doerner and L.
                      Hai$^*$ and L. Kaulen$^*$ and J. Ito$^*$ and M. van den Bent
                      and M. Taphoorn and A. A. Brandes and A. Idbaih and J.
                      Dômont and P. M. Clement and M. Campone and M. Bendszus and
                      A. von Deimling$^*$ and F. Sahm$^*$ and M. Platten$^*$ and
                      W. Wick$^*$ and A. Wick},
      title        = {{P}rognostic markers of {DNA} methylation and {NGS}
                      sequencing in progressive glioblastoma from the
                      {EORTC}-26101 trial.},
      journal      = {Clinical cancer research},
      volume       = {29},
      number       = {19},
      issn         = {1078-0432},
      address      = {Philadelphia, Pa. [u.a.]},
      publisher    = {AACR},
      reportid     = {DKFZ-2023-01512},
      pages        = {3892-3900},
      year         = {2023},
      note         = {#EA:B320# / 2023 Oct 2;29(19):3892-3900},
      abstract     = {The EORTC-26101 study was a randomized phase 2 and 3
                      clinical trial of bevacizumab in combination with lomustine
                      versus lomustine alone in progressive glioblastoma. Other
                      than for progression-free survival (PFS), there was no
                      benefit from addition of bevacizumab for overall survival
                      (OS). However, molecular data allows for the rare
                      opportunity to assess prognostic biomarkers from primary
                      surgery for their impact in progressive glioblastoma.We
                      analyzed DNA methylation array data and panel sequencing
                      from 170 genes of 380 tumor samples of the EORTC-26101
                      study. These patients were comparable to the overall study
                      cohort in regards of baseline characteristics, study
                      treatment and survival.295/380 $(78\%)$ of patients' samples
                      were classified into one of the main glioblastoma groups
                      receptor tyrosine kinase (RTK)1, RTK2 and mesenchymal. There
                      were 10 patients $(2.6\%)$ with isocitrate dehydrogenase
                      (IDH) mutant tumors in the biomarker cohort. Patients with
                      RTK1 and RTK2 classified tumors had lower median OS compared
                      to mesenchymal (7.6 vs. 9.2 vs. 10.5 months).
                      O6-methylguanine DNA-methyltransferase (MGMT) promotor
                      methylation was prognostic for PFS and OS. Neurofibromin
                      (NF)1 mutations were predictive of response to bevacizumab
                      treatment.Thorough molecular classification is important for
                      brain tumor clinical trial inclusion and evaluation. MGMT
                      promoter methylation and RTK1 classifier assignment were
                      prognostic in progressive glioblastoma. NF1 mutation may be
                      a predictive biomarker for bevacizumab treatment.},
      cin          = {B320 / HD01 / B300 / D170},
      ddc          = {610},
      cid          = {I:(DE-He78)B320-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)B300-20160331 / I:(DE-He78)D170-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37494539},
      doi          = {10.1158/1078-0432.CCR-23-0926},
      url          = {https://inrepo02.dkfz.de/record/277801},
}